Enanta Pharmaceuticals Inc insider trading
Every open-market purchase and sale by Enanta Pharmaceuticals Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Enanta Pharmaceuticals Inc’s insiders pay?
From October 2, 2013 to December 5, 2025, 17 insiders reported 6 open-market purchases and 25 sales not made under a pre-set plan in Enanta Pharmaceuticals Inc. Twelve months after each purchase was reported, the shares were +5.6% against the S&P 500 on average (median −9.5%), over 6 purchases with a full year of prices; 33% beat the index. After sales, the shares moved +3.2% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 18, 2014 into $19,303 by November 2, 2026, +5.5% a year. It held shares 29% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,080 (+5.0% a year), and held throughout $46,994 (+13.5%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Gardiner Nathaniel S. | Sr. VP & General Counsel | 2 | +1.1% (2) | 50% | 1 | −39.4% (1) | December 6, 2023 |
| Luly Jay R. | President and CEO | 1 | +71.5% (1) | 100% | 2 | −39.4% (1) | December 5, 2025 |
| Or Yat Sun | Chief Scientific Officer | 0 | — | — | 3 | −1.9% (2) | December 5, 2025 |
| Schuhsler Helmut | 10% owner | 0 | — | — | 3 | −22.6% (3) | March 5, 2014 |
| Buckley Stephen JR. | Director | 2 | −9.8% (2) | 0% | 0 | — | February 19, 2015 |
| Goldberg Marc E. | Director | 0 | — | — | 2 | +46.7% (2) | December 6, 2013 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | 0 | — | — | 2 | −39.4% (1) | December 5, 2025 |
| Luu Brendan | Chief Business Officer | 0 | — | — | 2 | −39.4% (1) | December 5, 2025 |
| Saints Capital Granite, L.P. | 10% owner | 0 | — | — | 2 | +90.8% (2) | October 11, 2013 |
| Vance Terry | Director | 1 | −20.5% (1) | 0% | 1 | −60.0% (1) | December 15, 2023 |
| Afting Ernst-Guenter | Director | 0 | — | — | 1 | +0.6% (1) | December 13, 2013 |
| Birner Hubert | 10% owner | 0 | — | — | 1 | −18.7% (1) | February 27, 2014 |
| Mellett Paul J | Sr. VP, Finance & Admin. & CFO | 0 | — | — | 1 | −39.4% (1) | December 6, 2023 |
| Obp (adjunct) III - Holdings LLC | 10% owner | 0 | — | — | 1 | +64.3% (1) | October 2, 2013 |
| Rottinghaus Scott T. | Chief Medical Officer | 0 | — | — | 1 | — | December 5, 2025 |
| Saints Capital Granite, LLC | 10% owner | 0 | — | — | 1 | +100.0% (1) | October 16, 2013 |
| Tvm Capital Gmbh | 10% owner | 0 | — | — | 1 | −28.1% (1) | February 20, 2014 |
When several insiders traded Enanta Pharmaceuticals Inc
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Enanta Pharmaceuticals Inc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +21.9% against the index. After 4 selling crowds, +22.5%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| December 31, 2025 | 5 selling | −13.1% | −18.7% | not yet |
| December 29, 2023 | 7 selling | +64.3% | +26.7% | −63.8% |
| February 27, 2015 | 2 buying | +13.5% | +21.9% | −14.5% |
| February 28, 2014 | 6 selling | −0.8% | +10.5% | −18.7% |
| October 31, 2013 | 3 selling | +85.0% | +71.4% | +98.5% |